Genentech Reports Profit Rise
Genentech (DNA) delivered a 1-cent earnings beat for the third quarter and surpassed expectations with sales of cancer-drug Avastin Monday. Sales of other products, however, fell shy of consensus targets, realizing recent analyst predictions following the release of soft prescription data.
The company reported earning 73 cents a share, or $778 million, before items, compared to 59 cents a share, or $637 million, in 2006.
Analysts surveyed by Thomson financial were looking for 72 cents a share on revenue of $2.93 billion. Genentech reported revenue of $2.91 billion before items (and including $3 million associated with the acquisition of Tanox), a 22% increase over operating revenue of $2.38 billion in the third quarter of 2006.
Despite the dose reduction in Avastin, the company beat the consensus target of $586 million, reporting sales of $597 million, compared to $435 million in the year-ago quarter. It also surpassed Street expectations of $585 million.Genentech was expected to miss targets at least slightly for Rituxan, for non-Hodgkin's lymphoma and as a combination therapy for rheumatoid arthritis, and Lucentis, for wet-age related macular degeneration (AMD), on the basis of recent prescription data. The consensus was $588 million and $210 million, respectively. The company reported Rituxan sales of $572 million, compared to $509 million in the year-ago quarter, and Lucentis sales of $198 million, compared to $153 million in the same quarter in 2006. Sales of breast cancer treatment Herceptin were $320 million, compared to $302 million in the year-ago quarter, and falling short of the consensus target of $339 million. Sales of Tarceva were $101 million compared to $100 million in 2006, and also falling shy of the Wall Street consensus of $111 million. Genentech reaffirmed previous non-GAAP earnings guidance for fiscal 2007 of $2.85 to $2.95 a share, a 28%-32% increase in comparison to 2006. The consensus target is on the high end of that, at $2.95. Shares were falling $1.13, or 1.5%, to $76.37 in after-hours trading.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV